Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects



Status:Completed
Conditions:HIV / AIDS, HIV / AIDS, HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:1/17/2018
Start Date:October 31, 2011
End Date:December 26, 2016

Use our guide to learn which trials are right for you!

A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral naïve Adult Subjects

This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy
(ART)-naïve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg
once daily (approximately 234 subjects) or darunavir/ritonavir (DRV/r) 800 mg/100 mg once
daily (approximately 234 subjects), each in combination with fixed-dose dual nucleoside
reverse transriptase inhibitor (NRTI) therapy (either abacavir/lamivudine (ABC/3TC) or
tenofovir/emtricitabine (TDF/FTC). Subjects will be stratified by screening HIV-1 RNA and
background NRTI selection. The primary analysis will take place after the last subject
completes 48 weeks on therapy; an additional analysis will be conducted after the last
subject completes Week 96 on study.

ING114915 is a Phase IIIb randomized, open-label, active-controlled, multicentre, parallel
group, fully-powered non-inferiority study. The study will be conducted in approximately 468
HIV-1 infected ART-naïve subjects. Subjects will be randomized 1:1 to receive DTG 50 mg once
daily (approximately 234 subjects) or DRV/r 800 mg/100 mg once daily (approximately 234
subjects), each in combination with fixed-dose dual NRTI therapy (either ABC/3TC or TDF/FTC).
The primary analysis will take place after the last subject completes 48 weeks on therapy; an
additional analysis will be conducted after the last subject completes Week 96 on study.

Subjects who fulfil eligibility requirements will be randomized 1:1 to receive DTG 50 mg once
daily or DRV/r 800 mg/100 mg once daily. In order to achieve balance across the two treatment
groups of the study, randomization will be stratified by: screening plasma HIV-1 RNA >/
100,000 copies/mL (c/mL) or > 100,000 c/mL and background dual NRTI (ABC/3TC or TDF/FTC) The
DTG and DRV/r doses will be administered in an open-label fashion throughout the study.

Subjects randomized to receive DTG and who successfully complete 96 weeks of treatment will
continue to have access to DTG until either it is locally approved and commercially
available, the patient no longer derives clinical benefit, the patient meets a
protocol-defined reason for discontinuation or until development of DTG is terminated.
Subjects randomized to the DRV/r arm will receive DRV/r through their Week 96 visit, after
which they will be discontinued from the study and will need to make alternative arrangements
to access antiretroviral medication. All subjects will receive background dual-NRTI therapy
through their Week 96 visit.

Inclusion Criteria:

- HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible
to enter and participate in the study if she is (1) non-childbearing potential, (2)
child bearing potential with negative pregnancy test at screening and Day 1 and agrees
to use protocol-specified methods of birth control while on study.

- HIV-1 infection with a screening plasma HIV-1 RNA greater than or equal to
1000copies/mL

- Antiretroviral-naïve (less than or equal to 10 days of prior therapy with any
antiretroviral agent following a diagnosis of HIV-1 infection)

- Signed and dated written informed consent is obtained from the subject or the
subject's legal representative prior to screening

Exclusion Criteria:

- Women who are pregnant or breastfeeding

- Any evidence of an active Centers for Disease and Prevention Control (CDC) Category C
disease [CDC, 1993], except cutaneous Kaposi's sarcoma not requiring systemic therapy

- Subjects with moderate to severe hepatic impairment (Class B or C) as determined by
Child-Pugh classification

- Anticipated need for Hepatitis C virus (HCV) therapy during the study

- History or presence of allergy or intolerance to the study drugs or their components
or drugs of their class

- History of malignancy within the past 5 years or ongoing malignancy other than
cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous
squamous cell carcinoma; other localized malignancies require agreement between the
investigator and the Study medical monitor for inclusion of the subject

- Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

- Treatment with any of the following agents within 28 days of Screening: radiation
therapy; cytotoxic chemotherapeutic agents; any immunomodulators

- Treatment with any agent, except recognized ART as allowed above, with documented
activity against HIV-1 in vitro within 28 days of first dose of investigational
product

- Exposure to an experimental drug or experimental vaccine within either 28 days, 5
half-lives of the test agent, or twice the duration of the biological effect of the
test agent, whichever is longer, prior to the first dose of investigational product

- Any evidence of primary viral resistance based on the presence of any major
resistance-associated mutation [IAS-USA, 2010] in the Screening result or, if known,
any historical resistance test result

- Any verified Grade 4 laboratory abnormality. Any acute laboratory abnormality at
Screening, which, in the opinion of the Investigator, would preclude the subject's
participation in the study of an investigational compound is exclusionary

- Alanine aminotransferase (ALT) greater than 5 times the upper limit of normal

- ALT greater than 3 times the upper limit of normal and bilirubin greater than or equal
to 1.5 times the upper limit of normal (with greater than 35% direct bilirubin)

- Subject has creatinine clearance of less than 50 mL/min via Cockroft-Gault method

- Recent history (less than or equal to 3 months) of any upper or lower gastrointestinal
bleed, with the exception of anal or rectal bleeding
We found this trial at
29
sites
Washington, District of Columbia 20007
1127
mi
from
Washington,
Click here to add this to my saved trials
Augusta, Georgia 30909
931
mi
from
Augusta, GA
Click here to add this to my saved trials
Aurora, Colorado 80010
403
mi
from
Aurora, CO
Click here to add this to my saved trials
Birmingham, Alabama 35249
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
1043
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28203
957
mi
from
Charlotte, NC
Click here to add this to my saved trials
Cincinnati, Ohio 45229
727
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dallas, Texas 75230
340
mi
from
Dallas, TX
Click here to add this to my saved trials
Daytona Beach, Florida 32117
1127
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Decatur, Georgia 30033
805
mi
from
Decatur, GA
Click here to add this to my saved trials
Denver, Colorado 80206
407
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48202
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Kansas City, Missouri 64128
199
mi
from
Kansas City, MO
Click here to add this to my saved trials
Longview, Texas 75605
402
mi
from
Longview, TX
Click here to add this to my saved trials
Los Angeles, California 90025
1179
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Macon, Georgia 31201
867
mi
from
Macon, GA
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
551
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Montpellier Cedex 5, 34295
1171
mi
from
Montpellier Cedex 5,
Click here to add this to my saved trials
Norwalk, Connecticut 06850
1316
mi
from
Norwalk, CT
Click here to add this to my saved trials
Orlando, Florida 32806
1144
mi
from
Orlando, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Portland, Oregon 97227
1384
mi
from
Portland, OR
Click here to add this to my saved trials
Providence, Rhode Island 02903
1424
mi
from
Providence, RI
Click here to add this to my saved trials
Savannah, Georgia 31405
1020
mi
from
Savannah, GA
Click here to add this to my saved trials
Seattle, Washington 98109
1411
mi
from
Seattle, WA
Click here to add this to my saved trials
Springfield, Massachusetts 01199
1364
mi
from
Springfield, MA
Click here to add this to my saved trials
Tampa, Florida 33612
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
Vero Beach, Florida 32960
1227
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
971
mi
from
Winston-Salem, NC
Click here to add this to my saved trials